# US 2022/0025064 A1 · Antibody therapeutics that bind cd137

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0025064 A1
- Document ID: US20220025064A1
- Status: Published application
- Kind: A1
- Application number: 17/499,127
- Filed: 2021-10-12
- Published: 2022-01-27
- Earliest claimed: 2015-02-22
- Assignees: Sorrento Therapeutics, Inc.
- Applicants: Sorrento Therapeutics, Inc.
- Inventors: John Dixon GRAY; Heyue ZHOU
- Web page: https://patentgrep.com/patent/US20220025064A1

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

There is disclosed compositions and methods relating to or derived from anti-CD137 antibodies. More specifically, there is disclosed fully human antibodies that bind CD137, CD137-antibody binding fragments and derivatives of such antibodies, and CD137-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression. Diseases amenable to treatment is selected from the group consisting of cancers, autoimmune diseases and viral infections.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

An isolated anti-CD137 antibody, or antigen-binding fragment thereof, comprising a heavy chain variable domain comprising complementarity determining regions (CDRs) as set forth in a heavy chain variable region amino acid sequence of SEQ ID NO: 17 and a light chain variable region comprising CDRs as set forth in a light chain variable region amino acid sequence of SEQ ID NO. 18.

### Claim 22 (depends on 21)

The antibody of claim 21, which is a fully human anti-CD137 antibody of an IgG class.

### Claim 23 (depends on 21)

The antibody or antigen-binding fragment thereof of claim 21, wherein the antibody has a heavy chain variable region sequence having at least 95% identity to SEQ ID NO. 17 and a light chain variable region sequence having at least 95% identity to SEQ ID NO. 18.

### Claim 24 (depends on 21)

The antibody or antigen-binding fragment thereof of claim 21, wherein the antibody has a heavy chain variable region sequence of SEQ ID NO. 17 and a light chain variable region sequence of SEQ ID NO. 18.

### Claim 25 (depends on 22)

The antibody of claim 22, wherein the antibody has a heavy chain variable region sequence of SEQ ID NO. 17 and a light chain variable region sequence of SEQ ID NO. 18.

### Claim 26 (depends on 21)

The antigen-binding fragment of claim 21, wherein the fragment is a Fab fragment or a single chain antibody comprising a heavy chain variable domain and a light chain variable domain which are connected by a peptide linker.

### Claim 27 (depends on 25)

The antigen-binding fragment of claim 25, wherein the antibody fragment has a heavy chain variable region sequence of SEQ ID NO. 17 and a light chain variable region sequence of SEQ ID NO. 18.

### Claim 28 (depends on 21)

A method of treating cancer or another disease requiring either stimulation of an immune response or suppression in a subject in need thereof, the method comprising administering an effective amount of the antibody of claim 21, such that the cancer or other disease is treated.

### Claim 29 (depends on 28)

The method of claim 28, wherein the cancer comprises ovarian cancer, colorectal cancer, melanoma, hepatocellular carcinoma, renal cancer, breast cancer, head and neck cancer, lung cancer or liver cancer.

### Claim 30 (depends on 28)

The method of claim 28, wherein the antibody has a heavy chain variable region sequence of SEQ ID NO. 17 and a light chain variable region sequence of SEQ ID NO. 18.

### Claim 31 (depends on 28)

The method of claim 28, wherein the other disease comprises an autoimmune disease.

### Claim 32 (depends on 31)

The method of claim 31, wherein the autoimmune disease comprises multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, or myasthenia gravis.

### Claim 33

An isolated nucleic acid encoding an anti-CD137 antibody, or antigen-binding fragment thereof, comprising a heavy chain variable domain comprising complementarity determining regions (CDRs) as set forth in a heavy chain variable region amino acid sequence of SEQ ID NO: 17 and a light chain variable region comprising CDRs as set forth in a light chain variable region amino acid sequence of SEQ ID NO. 18.

### Claim 34 (depends on 33)

The nucleic acid of claim 33, wherein the antibody has a heavy chain variable region sequence of SEQ ID NO. 17 and a light chain variable region sequence of SEQ ID NO. 18.

### Claim 35 (depends on 33)

An expression vector comprising the nucleic acid of claim 33.

### Claim 36 (depends on 33)

A host cell comprising the nucleic acid of claim 33.

### Claim 37 (depends on 36)

A method of making an anti-CD137 antibody, comprising culturing the host cell of claim 36 under conditions wherein the antibody is expressed.
